Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03415802
Other study ID # CH-GI-062
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 11, 2015
Est. completion date July 11, 2019

Study information

Verified date January 2021
Source Chinese Academy of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pancreatic cancer is a common malignancy of digestive system with gradually increasing incidence, is the fourth and seventh leading cause of cancer-related mortality in the world (1) and China (2) according to the statistics in 2014. The vast majority of patients were confirmed as locally advanced or distantly metastatic disease at diagnosis with an estimated five-year survival rate of 4% (3) due to occlusive development and rapid progress. Advanced pancreatic cancer is characterized by poor prognosis.


Description:

Gemcitabine has been approved as the standard chemotherapy for advanced pancreatic cancer since 1996, but the efficacy is extremely limited by a response rate of 6-8%, and median survival of 5.5-7 months. However, Gemcitabine-based combination treatments fail to transcend GEM monotherapy on overall survival, including GEM + 5-Fu [10], GEM + Oxaliplatin[11], and GEM + Irinotecan [12] and GEM + Cisplatin [13] (7-8) . Until 2011, Conroy et al.[15] reported that FOLFIRINOX solutions significantly improved ORR (31.6% vs 9%, P=0.0008), PFS (6.4 vs. 3.3 months, P<0.0001) and OS (11.1 vs. 6.8 months, P<0.001) than GEM single-agent, but the significant increase of grade 3/4 adverse reactions, to some extent, limited its wide application. Therefore, it is necessary to continue to explore effective and safe chemotherapy of advanced pancreatic cancer. Nab-Paclitaxel was approved by FDA for advanced pancreatic cancer in September 2013. S-1 has demonstrated potential value in the treatment of advanced pancreatic cancer as a new compound oral 5-FU(4-5) and has been approved for pancreatic cancer treatment in Japan. We conducted a single arm, prospective, phase II study in our center on the first-line treatment of advanced pancreatic cancer with nab-Paclitaxel and S-1 to investigate the efficacy and safety of the combination regimen.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date July 11, 2019
Est. primary completion date July 11, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age, years: 18-75 - Histologically and cytologically confirmed advanced pancreatic cancer , inresectable, measurable lesions according to RECIST criteria; ECOG score of 0-1; life expectancy =12 weeks; - Untreated; more than 6 months after the last adjuvant chemotherapy (does not include taxanes and S1); - Laboratory examination within 14 days before entering the study should meet following requirements: ANC = 1.5 x 10^9/L; PLT = 100 x 10^9/L; Hb = 90g/L (9g/dL); AST, ALT = 2.5 x ULN (with no liver metastasis), = 5 x ULN(with liver metastasis); creatinine = 1.5 x ULN; TBIL = 1.5 x ULN - Both male and female subjects of potential fertility have to agree effective birth control during the entire study - Informed consent Exclusion Criteria: - Concurrent other effective treatment (including radiotherapy) - Resectable patients - Allergy history to other drugs in the same class patients with pregnancy or lactation - Known severe internal medical diseases - Abnormal heart function or relevant history of myocardial infarction and severe arrhythmia - Immunocompromised patients, such as HIV positive - Uncontrollable mental illness - Other conditions the researchers considered ineligible for the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nab-paclitaxel and S-1
Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area < 1.25 m2; 50mgBID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-14, q3w)

Locations

Country Name City State
China National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College Beijing

Sponsors (1)

Lead Sponsor Collaborator
Aiping Zhou

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate(ORR) CR+PR was defined as objective response rate (ORR) 6 month
Secondary DCR CR+PR+SD was defined as disease control rate (DCR) 6 month
Secondary PFS From date of randomization until date of first documented PD, date of death 6 month
Secondary OS From date of randomization until date of death 1 year
Secondary Safety profile: Adverse events of nab-Paclitaxel plus S-1 for advanced pancreatic cancer Adverse events of nab-Paclitaxel plus S-1 for advanced pancreatic cancer 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Not yet recruiting NCT03662035 - Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer Phase 2
Recruiting NCT05085548 - ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies Phase 1
Recruiting NCT06111274 - A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT04137536 - A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer Phase 1
Completed NCT04617067 - Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT04469556 - Pancreatic Adenocarcinoma Signature Stratification for Treatment Phase 2
Recruiting NCT04104672 - A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Phase 1
Not yet recruiting NCT05100329 - A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer Phase 2
Completed NCT02101580 - Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer Phase 1
Not yet recruiting NCT06329947 - A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD Phase 2
Recruiting NCT02135822 - Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer Phase 2
Recruiting NCT04803851 - Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT05162118 - Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04643405 - APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma Phase 1/Phase 2
Recruiting NCT03889795 - Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors Phase 1
Completed NCT01303172 - A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT06422156 - SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT04931381 - Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer Phase 3
Recruiting NCT04482257 - Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. Phase 1